Virtu Financial LLC Takes $1.17 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Virtu Financial LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 8,782 shares of the life sciences company’s stock, valued at approximately $1,173,000.

A number of other institutional investors have also made changes to their positions in the company. Empowered Funds LLC increased its holdings in shares of Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after acquiring an additional 66 shares during the last quarter. Bank of Stockton increased its holdings in shares of Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after acquiring an additional 80 shares during the last quarter. Caprock Group LLC increased its holdings in shares of Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after acquiring an additional 83 shares during the last quarter. Stephens Inc. AR increased its holdings in shares of Illumina by 1.4% in the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after acquiring an additional 90 shares during the last quarter. Finally, Spire Wealth Management increased its holdings in shares of Illumina by 26.0% in the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after acquiring an additional 97 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of analyst reports. Piper Sandler boosted their price objective on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Hsbc Global Res lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Canaccord Genuity Group reduced their price objective on Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, March 11th. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and reduced their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Guggenheim reduced their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $140.90.

Illumina Trading Up 3.4 %

Shares of Illumina stock opened at $87.66 on Monday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market cap of $13.89 billion, a price-to-earnings ratio of -11.41, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The business has a fifty day simple moving average of $108.20 and a 200-day simple moving average of $128.26. Illumina, Inc. has a fifty-two week low of $80.18 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.